Search This Blog

Monday, February 5, 2024

Migrant moped gang busted in attacks as pedestrian violently dragged along NYC street

 Two men were busted as part of a moped-riding migrant crew that have been snatching cellphones right out of New Yorkers hands in daring bursts of street crime — and police sources say they’ve already flipped on the ringleader.

The two suspects — Cleyber Andrade, 19, and Juan Uzcatgui, 23 — are allegedly part of a wider ring whose members are connected to 62 different instances of grand larceny throughout the Big Apple, police sources told The Post.

But cops are still searching for the main man, a migrant named Victor Parra who was cut loose by a judge in December after getting picked up for grand larceny, sources said.

At a Monday press conference, NYPD Inspector Nicholas Fiore said Parra has convinced others to “go do his dirty work to grab phones and stuff.”

“He’s the big target,” Fiore said in a video posted to X. “He’s caused a lot of problems in New York City. And hopefully we’ll grab him, we get some headway on this.”

Authorities hope to pick him the mastermind today — Andrade and Uzcatgui already flipped and gave him up, sources said.

The NYPD has arrested two men in connection to a crew of migrants who have been stealing cellphones while riding mopeds.NYPD
Cleyber Andrade, 19, and Juan Uzcatgui, 23, are allegedly connected to a ring responsible for 62 different instances of grand larceny.NYPD

Cops have also named six other people connected to the ring: Yan Jimenez, 25, of Manhattan; Anthony Ramos, 21, of Manhattan; Richard Saledo, 21, of the Bronx; Beike Jimenez, 21, of the Bronx; Maria Manaura, 32, of Manhattan; and Samuel Castro, 27, of Queens, according to sources.

All have previous grand larceny arrests for criminal activity sources say is related to the conspiracy. But they’re all free without bail ahead of their impending court dates, sources said.

The robbery ring — and others like it — worry law enforcement specifically because the migrants often have multiple aliases and swap identities and birthdays, turning them into so-called “ghost perps” who become very hard to track, sources said.

NYPD Inspector Nicholas Fiore said that the two suspects have already flipped on the crew’s “mastermind” Victor Parra.NYPD

Andrade and Uzcatgui, who apparently know each other from Colombia, were also arrested on Friday for allegedly committing back-to-back phone snatches on a stolen moped in Lower Manhattan.

Police sources say the two fled from Manhattan over the Robert F. Kennedy Bridge, but law enforcement spotted them on the BQE and arrested them afterward in Queens.

During the pursuit, the two dumped a bag that a good Samaritan later turned in at the 114th Precinct. Sources say it had three cellphones in it: two belonging to their victims, and one belonging to one of the suspects.

At some point after the arrest, the two gave up information that helped secure Monday’s warrant, which was ostensibly meant to snag Parra.

The police hope to arrest Parra on Monday.NYPD
Both men were charged individually Saturday with grand larceny for stealing a moped, resisting arrest and stolen property offenses.

During the off-topic portion of his Monday press conference, Mayor Adams commended the NYPD on its officers’ “speedy action” in apprehending the two.

“I take my hat off to the detectives who are involved in bringing this case to closure,” he said.

https://nypost.com/2024/02/05/metro/migrant-moped-crew-busted-after-stealing-cellphones-right-out-of-nyers-hands-sources/

'Exposure to Birth Defect Causing Meds Common Before Prenatal Care'

 Most prenatal exposure to teratogenic (birth defect vausing) medication happens before prenatal care is initiated, which is often after strict abortion ban cutoffs, a cross-sectional study found.

Among a sample of privately-insured people, 5.8% of pregnancies with live deliveries were exposed to teratogenic medications versus 3.1% of those with nonlive outcomes -- and that exposure happened by 6 weeks' gestation in a quarter of those pregnancies (1.3% of all pregnancies), reported Almut Winterstein, PhD, of the University of Florida's College of Pharmacy and Center for Drug Evaluation and Safety in Gainesville, and colleagues.

By that time, 84% of patients had not initiated prenatal care; on average, patients initiated prenatal care at 56 days, authors wrote in JAMA Network Openopens in a new tab or window.

Winterstein told MedPage Today that authors were "aware of the pattern of teratogen exposure during pregnancy, but we had not seen it in the context of prenatal care initiation," and that this research illuminates the magnitude of the problem.

"We wanted to quantify what proportion of pregnancies with teratogenic exposure has the opportunity to discuss the risk with their prenatal care provider and consider pregnancy termination," Winterstein said.

Of the 639,994 total pregnancies, nearly three-quarters were live deliveries, while a quarter had a nonlive outcome, such as abortion or stillbirth. Live deliveries had a mean maternal age of 30.9 versus 31.6 for those with nonlive outcomes. Out of the total, 32,500 pregnancies were exposed to teratogenic medicine at any time during gestation.

By 15 weeks' gestation, teratogenic medicine exposure had occurred in nearly half of all exposed pregnancies (2.5% of all pregnancies). Yet, among live deliveries, 16.8% still had yet to initiate care, which was even higher at 58.3% among nonlive outcomes.

One in 16 pregnancies are exposed to potentially teratogenic medications, which can cause fetal abnormalities, and the highest exposure happens in the first trimester.

"While some of these exposures result in pregnancy loss, others are not known before delivery and result in infant death or serious lifelong outcomes," Winterstein said, also urging lawmakers to consider further abortion exceptions for risk for serious birth defects. Winterstein said future research should look at what leads to pregnancies exposed to teratogenic medications in order to improve risk mitigation strategies.

"If prenatal exposure to teratogenic medications occurs, it is critical that prenatal care be initiated expeditiously to allow physician-patient discussions about pregnancy termination within legal abortion windows," authors concluded.

Authors used the MarketScan Commercial Database, which keeps billing data for people with employer-sponsored health insurance in the U.S., to look at pregnancies that ended between January 2017 and December 2019 among individuals who had continuous health plan enrollment from 90 days prior to conception and 30 days after pregnancy end.

They tracked 137 teratogenic medicines, the most common being those that acted on the renin angiotensin system, anticonvulsants, systemic antimycotics, antineoplastics, isotretinoin, and warfarin. They excluded sex hormones, infertility treatments, opioids, misoprostol, methotrexate, and ergotamine derivatives. The 2 weeks between the last menstrual period and conception was excluded from the analysis.

They measured medication utilization with National Drug Codes on pharmacy claims and medical encounter claims with Healthcare Common Procedure Coding System codes. Prenatal care initiation was based on encounters with obstetricians or other doctors that were coded indicating prenatal care or pregnancy. A previously developed algorithm identified pregnancy episodes. Analysis was based on three common gestational age cutoffs for abortion laws: 6, 15, and 22 weeks.

Authors note that teratogenic medication exposure was higher among nonlive pregnancies and it was possible the algorithm missed pregnancies that didn't result in reimbursed clinical care, such as some elective abortions. Another limitation is the possibility of overestimating gestational age, which could result in overestimating prenatal exposure. Additionally, it's possible pregnant people talked with their doctor via phone or message prior to a visit, though it's unlikely teratogenic risk would be discussed at that time.

Disclosures

Winterstein reported receiving grants from Merck Sharp & Dohme as well as personal fees from Merck Sharp & Dohme, Bayer KG, Ipsen, Arbor Pharmaceuticals, and Genentech.

Co-authors reported receiving personal fees from Harmony Biosciences, Axsome Therapeutics, Biohaven, and Myovant Sciences to serve on pregnancy registry scientific advisory committees.

Primary Source

JAMA Network Open

Source Reference: opens in a new tab or windowWinterstein AG, et al "Prenatal care initiation and exposure to teratogenic medications" JAMA Netw Open 2024; DOI: 10.1001/jamanetworkopen.2023.54298.


https://www.medpagetoday.com/obgyn/pregnancy/108571

First patient treated with Moderna's PD-1/IDO1 cancer shot

 The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect tumours from attack by the immune system.

Injections of the mRNA-4359 vaccine have started in the UK at Imperial College Healthcare NHS Trust in the Mobilize study, which aims to enrol almost 200 patients with advanced solid tumours, including melanoma, lung, breast, and head and neck cancers, at several centres around the world.

The first patient to receive the therapy is an 81-year-old man from Surrey with treatment-resistant malignant melanoma.

PD-L1 is a cell surface receptor expressed on both tumour and regulatory immune cells and functions as a checkpoint to inhibit T-cell function, while IDO1 is an enzyme involved in T-cell suppression and immune tolerance.

The mRNA-based vaccine is designed to instruct the body to generate antibodies against PD-L1 and IDO1 through a course of intramuscular injections given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment for various cancers, including melanoma and non-small cell lung cancer (NSCLC), over six months.

The main aim of the study is to assess the safety of mRNA-4359 and its ability to stimulate antibodies against PD-L1 and IDO1, but it will also investigate whether the vaccine or combination with Keytruda can actively shrink tumours. Results are due in 2027, with patients followed up for two years after the treatment completes.

The first patient to receive the vaccine, who wishes to remain anonymous, said that being able to participate in the trial was “a relief. I knew from my original diagnosis that I had something that was never going to go away, or unlikely to go away.”

He added: “Taking part in a trial gives you a sense that you’re contributing to something which can help a lot of other people. You’re also clearly doing it for personal reasons, but it’s a mixture of those two.”

The results of the study will be closely watched to see if a new generation of mRNA-based vaccines can reproduce in oncology the dramatic results seen with the technology in infectious diseases like COVID-19.

Moderna and partner MSD have already advanced one mRNA vaccine called mRNA-4157 (also V940) into phase 3 trials alongside Keytruda in NSCLC and melanoma, used as an adjuvant therapy for earlier-stage tumours that can be treated with surgery. Results are due from 2029 onwards.

The partners seem to be a little ahead of BioNTech – Moderna’s arch-rival in the COVID-19 vaccine category – when it comes to applying the technology to cancer. BioNTech is also developing its BNT111 vaccine for relapsed/refractory melanoma that is in mid-stage testing in combination with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab), with results due next year.

Dr David Pinato, a consultant medical oncologist at Imperial College Healthcare NHS Trust and investigator of the UK arm of the Mobilize trial, said: “This research is still in the early stages and may be a number of years from being available to patients, but this trial is laying crucial groundwork that is moving us closer towards new therapies that are potentially less toxic and more precise. We desperately need these to turn the tide against cancer.”

https://pharmaphorum.com/news/first-patient-treated-modernas-pd-1ido1-cancer-shot

2 upgrades for Cigna

 

TodayUpgradeRBC Capital MktsSector Perform → Outperform$327 → $354
TodayUpgradeCantor FitzgeraldNeutral → Overweight$334 → $372

'White House says Iraq should do more to combat militia groups that attack US'

 White House national security spokesperson John Kirby said Sunday that the Iraqi government should work with the U.S. to combat the threat posed by militia groups on its own soil.

In an interview on “Fox News Sunday” with Shannon Bream, Kirby reaffirmed the United States’s commitment to respond to any attack on U.S. troops “as aggressively as we need to” when asked about the Iraqi government’s criticism of the U.S. retaliatory strikes on Friday.  

“We’ve got to take seriously the attacks on our troops and our facilities. In this case, in Jordan, three Americans were killed, three troops, three families now are grieving,” Kirby told Bream.

“The president’s not going to sit back and idly just take that. We’re going to respond. We’re going to respond as aggressively as we need to,” he added.

Kirby would not get into the details about what the exact discussions were between the United States and the Iraqi governments but said, “There were appropriate notifications and discussions with the Iraqi government. I’ll leave it at that.”

He called on the Iraqi government to assist the U.S.

“But we also want to see the Iraqi government move with more alacrity to help us rid the threat of these militia groups on Iraqi soil. That should be — they should consider a violation of their sovereignty, that these groups are operating with some manner of impunity on Iraqi soil,” Kirby continued.

The interview comes after the U.S. military began its first round of airstrikes on Iranian-backed groups in Syria and Iraq on Friday, in response to an attack on a base in Jordan that killed three American troops and injured about 40 others. A second round of airstrikes, launched by the U.S. and Britain, took place the next day against Houthi rebels in Yemen — a group also backed by Iran.

White House national security adviser Jake Sullivan said Sunday that the U.S. intends to continue launching strikes against the Iranian-backed groups.

“It began with strikes on Friday night, but that is not the end of it. We intend to take additional strikes and additional action to continue to send a clear message that that the United States will respond when our forces are attacked, or people are killed,” Sullivan said Sunday on NBC News’s “Meet the Press.”

https://thehill.com/policy/defense/4447879-white-house-says-iraq-should-do-more-to-combat-militia-groups-that-attack-us/

CDC relaunches anti-smoking ad campaign with focus on menthol

 The Centers for Disease Control and Prevention (CDC) on Monday relaunched an anti-smoking ad campaign, with a particular focus on the dangers of menthol cigarettes.  

Many of this year’s ads shown as part of the “Tips From Former Smokers” campaign include messaging about the harms of menthol cigarettes

The “Tips” campaign initially ran from 2012-18 and features messages from people living with serious long-term health effects from smoking and secondhand smoke exposure. CDC credits it with helping 1 million people successfully quit smoking. 

Scientists have long known that menthol in cigarettes can make them more addictive. Menthol creates a cooling sensation in the throat and airways, making the smoke feel less harsh and easier to inhale. 

Public health experts, including the CDC, say banning the sale of menthol cigarettes could save hundreds of thousands of lives, particularly among Black smokers. An estimated 85 percent of Black smokers use menthol cigarettes, according to federal statistics.  

Congress banned flavored cigarettes as part of the 2009 law giving the Food and Drug Administration authority to regulate tobacco products, but a loophole exempted menthol. 

The Biden administration first proposed a ban on menthol cigarette sales in 2022. The administration was set to publish a final rule in December, but then quietly delayed it until at least March after critics argued the ban would unfairly target Black smokers. 

Anti-tobacco advocates are growing increasingly concerned that a divided White House will bow to political pressure from the tobacco industry and scrap the plan completely, amid concerns of a backlash among Black voters ahead of the 2024 election.  

https://thehill.com/policy/healthcare/4449060-cdc-relaunches-anti-smoking-ad-campaign-menthol/

Karyopharm up on coattails of MorphoSys

 

Sympathy move in Karyopharm Therapeutics. MorphoSys AG (NASDAQ:MOR) ADRs soared 45% amid takeover report.